Adiponectin is essential in prostate cancer prevention and management because it has anti angiogenic activity also trough activation of AMPK-TSC pathway (resulting in inhibition of mTOR activation) in fact patients affected by aggressive and metastatic prostate cancer has lower blood levels of adiponectin. The gene discussed is ADIPOQ; the disease is metastatic prostate carcinoma.